ABNOM
☆ AI Dermatology — Free Service
В резултатите от Stiftung Warentest за 2022 г. в Германия, потребителското удовлетворение от ModelDerm е само малко по-ниско, отколкото при платените телемедицински консултации.
В резултатите от Stiftung Warentest за 2022 г. в Германия, потребителското удовлетворение от ModelDerm е само малко по-ниско, отколкото при платените телемедицински консултации.
relevance score : -100.0%
ReferencesИзвестно е, че Q‑switched Nd:YAG лазерът ефективно лекува невус на Ota и подобни състояния. Проведохме проучване, за да оценим колко добре high‑fluence 1064 nm Q‑switched Nd:YAG лазер работи върху монголски петна в необичайни области, без да предизвиква изсветляване на кожата. Изследвахме 61 пациенти с тези петна, като общо оценихме 70 лезии. Половината от лезиите бяха третирани с лазер, а останалите оставени нелекувани за сравнение. Резултатите бяха оценени със скала и с устройство Mexameter® за измерване на нивата на меланин. Пациентите бяха проследявани средно 14 месеца в групата за лечение и 18 месеца в наблюдателната група. В края на проучването открихме значителни разлики в резултатите по скалата и в нивата на меланин между третираната и нетретираната група, като групата, третирана с лазер, показва по‑добри резултати. Лазерът high‑fluence Q‑switched Nd:YAG, без да предизвика изсветляване на кожата, се оказа ефективен и безопасен за лечение на тези необичайни монголски петна.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
Проучихме ефективността и безопасността на конкретно лазерно лечение за ABNOM и разгледахме факторите, които могат да повлияят на неговата ефективност. Включихме 110 пациенти с ABNOM, получаващи между две и девет лазерни процедури. Установихме, че лечението е по‑ефективно, колкото по‑дълго се прилага, но е по‑мало ефективно при по‑възрастни пациенти. Също така то работи по‑добре при пациенти със светла кожа (тип III) и при по‑малки засегнати участъци (по‑малко от 10 cm²). Наличието на мелазма в комбинация с ABNOM намалява ефективността на лечението. Цветът и броят на засегнатите зони не оказват значително влияние. Около 10 % от пациентите развиха по‑тъмни петна след лечението. Ранното многократно лечение даде добри резултати. По‑възрастните пациенти със тъмна кожа и предишни тъмни петна са по‑склонни да получат нови тъмни петна след процедурата. За пациенти с ABNOM и мелазма се препоръчва използването на лазер с по‑ниска енергия, за да се избегне влошаване на мелазмата.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
○ Лечение
Избелващите агенти рядко помагат. За разлика от мелазмата, ABNOM може да се подобри с лазерно лечение и да се отстрани без рецидив. Лазерното лечение обикновено се провежда 10‑20 пъти за ABNOM.
#QS1064 laser